Skip to main content
. Author manuscript; available in PMC: 2012 Dec 5.
Published in final edited form as: Cancer Res. 2011 Aug 25;71(20):6360–6370. doi: 10.1158/0008-5472.CAN-11-0362

Figure 3. Kaplan-Meier estimates of relapse-free survival (RFS) for early stage breast cancer patients with NR3C1-high versus -low tumors, by ESR1 status.

Figure 3

Tumors in the top quartile of NR3C1 expression were identified as “NR3C1-high,” while tumors in the bottom quartile of NR3C1 expression were identified as “NR3C1-low.” A, ESR1+ untreated NR3C1-high patients (n=87) had a better outcome (p=0.03, log-rank test; HR=0.60) than NR3C1-low untreated patients (n=151). B, ESR1−/ NR3C1-high patients who did not receive adjuvant chemotherapy (n=71) had a worse outcome (p=0.001, log-rank test; HR=2.23) than NR3C1-low untreated patients (n=61). C, ESR1+/NR3C1-high patients (n=136) who received adjuvant tamoxifen treatment had a significantly better outcome (p=7.75e-8, log-rank test; HR=0.25) than ESR1+ / NR3C1-low adjuvant tamoxifen treated patients (n=68). D, ESR1− / NR3C1-high patients who received adjuvant chemotherapy treatment (n=18) had a significantly worse RFS (p=5.8e-7, log-rank test; HR=6.83) than ESR1− / NR3C1-low adjuvant chemotherapy-treated patients (n=28).